Clinical Trials Search

Clinical Trial 19579

Study Title

Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy Fractionation for Patients with HPV+ Oropharyngeal Cancers.

Summary

This study is to determine whether a mathematical model can be used to choose a radiation delivery method to improve the rate of a rapid response.
Investigators hypothesize that using individual patient proliferation saturation index (PSI) to select radiotherapy fractionation (conventional fractionation or hyperfractionation) may improve the likelihood of a rapid response (defined as ≥ 32% reduction in volume at 4 weeks).

Objective

Primary Objective:We hypothesize that by using individual patient proliferation saturation index (PSI) to select radiotherapy fractionation (conventional fractionation or hyperfractionation) to improve the likelihood of a rapid response (defined as ¡Ý 32% reduction in volume at 4 weeks). Secondary Objectives:1)Rate of complete response by CT at 2 months or PET/CT at 3 months following completion of therapy. 2)Correlate response and outcome to pre-treatment and during treatment radiomics features on PET/CT/MRI. 3)Correlate response and outcome to mathematical models of tumor growth and death dynamics pre-treatment and during treatment. Primary Endpoint: For patients with squamous cancer of the head and neck, fractionation of radiation will be individualized based on their PSI. Response will be measured after 20 days of RT as assessed by CT or MRI, as described in section 10.0. Primary objective is to increase the rate of response of ¡Ý 32% at 20 days to 63% of patients, above the expected 49%.

> Stated willingness to comply with all study procedures and availability for the duration of the study

Male or female, aged ≥ 18 years

Pathologically (histologically or cytologically) proven diagnosis of p16+ or HPV+ squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx; cytologic diagnosis from a cervical lymph node is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, and may consist of pathology, palpation, imaging, or endoscopic evaluation, and should be sufficient to estimate the size of the primary (for T stage).

Request an Appointment at Moffitt Cancer Center

Thank you for your interest in scheduling an appointment with our expert team. Please call us at 1-888-663-3488 and a patient services specialist can assist you with scheduling or click on one of the links below to fill out our convenient online form.

NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.

RETURNING PATIENTS Since you are an established Moffitt patient, please call us directly to schedule your follow-up appointment at 1-888-663-3488.